New data validate scalable Omira™ OC ovarian cancer assay and reveal AOA Dx’s multi-omics platform potential across multiple cancer types
DENVER, CO, October 6, 2026: AOA Dx, a biotech company building a multi-omics liquid biopsy platform for earlier cancer detection, announced new data presented at MSACL and EDCC, that significantly broadens the capabilities of its technology beyond ovarian cancer.
AOA Dx has now demonstrated cancer-associated signals across ovarian, endometrial, and cervical cancers, including strong performance in early-stage disease. This follows the advancement of its lead ovarian cancer test, Omira™ OC (previously known as AKRIVIS GD™), from broad biomarker discovery into a targeted, clinical-grade assay designed to run on mass spectrometry and immunoassay infrastructure already used by high-throughput clinical laboratories.
Together, the data demonstrate a break-through in novel biomarker potential for the oncology field. AOA Dx is not only identifying coordinated metabolic changes associated with cancer biology across multiple diseases, it is demonstrating that those discoveries can be translated into reproducible assays built for clinical scale.
“We started with ovarian cancer, and we have always been building for something much bigger. We now have a clinical-grade ovarian cancer assay designed for commercial-scale infrastructure, while the biology behind our platform is showing strong signals across additional cancers. We are moving from one product to a pipeline of oncology diagnostics,” said Oriana Papin-Zoghbi, CEO and Co-Founder of AOA Dx.
Omira™ OC was developed from more than 9,000 candidate discovery features, now reduced to a simple, targeted panel of <10 features. In an independent hold-out patient set, Omira™ OC achieved an AUC of 0.97 for distinguishing ovarian cancer from symptomatic non-cancer conditions and 0.96 for early-stage (I/II) disease. It also maintained high specificity when challenged against conditions known to cause false positives with existing ovarian cancer biomarkers.
Omira™ OC is designed to run on mass spectrometry and immunoassay systems already operating in clinical laboratories, creating a path to commercial scale without requiring entirely new laboratory infrastructure.
AOA Dx also showed that the underlying biology extends beyond ovarian cancer. Using a targeted lipid panel, the platform demonstrated 95.7% sensitivity for early-stage endometrial cancer and 94.4% for early-stage cervical cancer at 90% specificity.
“This is what makes the data so exciting and meaningful,” said Abby McElhinny, Chief Scientific Officer of AOA Dx. “We have taken complex discovery and multi-omic data sets, translated them into a targeted and reproducible clinical assay, and are now seeing that the biological pathways extend across multiple cancers. That gives us a foundation of biomarkers to build well beyond our first indication. The potential for the early detection field and for other disease states is high.”
AOA Dx is already evaluating the platform in cancers outside gynecologic oncology, where early studies are showing encouraging signals. Additional data are expected to be presented at a later date.
About AOA Dx
AOA Dx is transforming early cancer detection with its proprietary platform, a first-of-its-kind, multi-omics liquid biopsy that integrates lipids, metabolites, proteins and clinical data using advanced machine learning. The company’s lead test, Omira™ OC, is designed to detect ovarian cancer early in symptomatic women, addressing a critical diagnostic gap in one of the deadliest cancers affecting women.
Based in Denver, Colorado, AOA Dx is led by an experienced team of scientists and industry veterans. The lab specializes in multi-omics analysis across lipidomics, metabolomics, and proteomics, powered by high-resolution mass spectrometry. By converting discovery-level data into validated, targeted assays, the platform enables repeatable, clinically scalable diagnostics with strong IP and regulatory pathways.